http://jcps.bjmu.edu.cn
Cost-utility of erlotinib combined with bevacizumab versus bevacizumab alone after completion of chemotherapy with bevacizumab for first-line treatment of advanced non-small-cell lung cancer
Fangbing Lv, Kewei Yu, Wenwen Gao, Shuwen Yu
Journal of Chinese Pharmaceutical Sciences . 2017, (6): 447 -454 .  DOI: 10.5246/jcps.2017.06.049

About Journal | Info for Authors | Statements | Peer Review Policy | Submission | Copyright Info
京ICP备05051953号-7
Copyright © Journal of Chinese Pharmaceutical Sciences, School of Pharmaceutical Sciences, Peking University
Tel./Fax: +86-10-82801713, E-mail: jcps@bjmu.edu.cn
Powered by Beijing Magtech Co., Ltd.